Stabilization of HIV-1 gp120-CD4 Receptor Complex through Targeted Interchain Disulfide Exchange*

HIV-1 enters cells via interaction between the trimeric envelope (Env) glycoprotein gp120/gp41 and the host cell surface receptor molecule CD4. The requirement of CD4 for viral entry has rationalized the development of recombinant CD4-based proteins as competitive viral attachment inhibitors and immunotherapeutic agents. In this study, we describe a novel recombinant CD4 protein designed to bind gp120 through a targeted disulfide-exchange mechanism. According to structural models of the gp120-CD4 receptor complex, substitution of Ser60 on the CD4 domain 1 α-helix with Cys positions a thiol in proximity of the gp120 V1/V2 loop disulfide (Cys126–Cys196), satisfying the stereochemical and geometric conditions for redox exchange between CD4 Cys60 and gp120 Cys126, and the consequent formation of an interchain disulfide bond. In this study, we provide experimental evidence for this effect by describing the expression, purification, refolding, receptor binding and antiviral activity analysis of a recombinant two-domain CD4 variant containing the S60C mutation (2dCD4-S60C). We show that 2dCD4-S60C binds HIV-1 gp120 with a significantly higher affinity than wild-type protein under conditions that facilitate disulfide exchange and that this translates into a corresponding increase in the efficacy of CD4-mediated viral entry inhibition. We propose that targeted redox exchange between conserved gp120 disulfides and nucleophilic moieties positioned strategically on CD4 (or CD4-like scaffolds) conceptualizes a new strategy in the development of high affinity HIV-1 Env ligands, with important implications for therapy and vaccine development. More generally, this chalcogen substitution approach provides a general means of stabilizing receptor-ligand complexes where the structural and biophysical conditions for disulfide exchange are satisfied.

[1]  R. Wyatt,et al.  Immunogenicity of HIV-1 envelope glycoprotein oligomers , 2009, Current opinion in HIV and AIDS.

[2]  C. Broder,et al.  Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity. , 2003, Vaccine.

[3]  S. Marsters,et al.  Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. , 1987, Science.

[4]  J. Sodroski,et al.  Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. , 1985, Science.

[5]  A. Trkola,et al.  Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. , 2000, The Journal of infectious diseases.

[6]  J. Sodroski,et al.  Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120 , 1994, Journal of virology.

[7]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[8]  B. Haynes,et al.  Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. , 1993, Journal of immunology.

[9]  Yasuhiro Suzuki,et al.  Characterization of a CD4-independent clinical HIV-1 that can efficiently infect human hepatocytes through chemokine (C-X-C motif) receptor 4 , 2008, AIDS.

[10]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[11]  R. Varadarajan,et al.  Protein minimization of the gp120 binding region of human CD4. , 2005, Biochemistry.

[12]  Zheng Yang,et al.  A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. West,et al.  Evaluation of CD4-CD4i Antibody Architectures Yields Potent, Broadly Cross-Reactive Anti-Human Immunodeficiency Virus Reagents , 2009, Journal of Virology.

[14]  D. Ho,et al.  Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[15]  W. Ou,et al.  Role of protein disulfide isomerase and other thiol-reactive proteins in HIV-1 envelope protein-mediated fusion. , 2006, Virology.

[16]  B. Trus,et al.  gp160, the envelope glycoprotein of human immunodeficiency virus type 1, is a dimer of 125-kilodalton subunits stabilized through interactions between their gp41 domains , 1991, Journal of virology.

[17]  E. Berger,et al.  sCD4-17b bifunctional protein: Extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates , 2010, Retrovirology.

[18]  D. Missé,et al.  Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes , 2003, Nature Biotechnology.

[19]  P. Hogg,et al.  Redox control on the cell surface: implications for HIV-1 entry. , 2003, Antioxidants & redox signaling.

[20]  Raghavan Varadarajan,et al.  Characterization of gp120 and Its Single-Chain Derivatives, gp120-CD4D12 and gp120-M9: Implications for Targeting the CD4i Epitope in Human Immunodeficiency Virus Vaccine Design , 2005, Journal of Virology.

[21]  T. Oas,et al.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Luis Moroder,et al.  Isosteric replacement of sulfur with other chalcogens in peptides and proteins , 2005, Journal of peptide science : an official publication of the European Peptide Society.

[23]  M. Osburne,et al.  Production of secreted, soluble human two-domain CD4 protein in Escherichia coli. , 1999, Journal of immunological methods.

[24]  D. Montefiori,et al.  Crosslinked HIV-1 envelope–CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Wyatt,et al.  Rational modifications of HIV-1 envelope glycoproteins for immunogen design. , 2007, Current pharmaceutical design.

[26]  P. Debré,et al.  Immunogenicity of HIV type 1 gp120 CD4 binding site phage mimotopes. , 2005, AIDS research and human retroviruses.

[27]  J. Bonifacino,et al.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[28]  W. C. Wang,et al.  Expression, purification, and characterization of a murine CD4 fragment containing the first two N-terminal domains. , 1997, Biochemical and biophysical research communications.

[29]  R. Gallo,et al.  Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens , 2007, Proceedings of the National Academy of Sciences.

[30]  Tongqing Zhou,et al.  Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain , 2009, Journal of Virology.

[31]  François Stricher,et al.  Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. , 2005, Structure.

[32]  D. Montefiori,et al.  Enhanced HIV-1 neutralization by a CD4-VH3-IgG1 fusion protein. , 2009, Biochemical and biophysical research communications.

[33]  R. Garlick,et al.  Escherichia coli expression, purification, and biological activity of a truncated soluble CD4. , 1990, AIDS research and human retroviruses.

[34]  B. Berkhout,et al.  Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein. , 2008, Molecular biology of the cell.

[35]  E. Levy,et al.  Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Koup,et al.  Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. , 1995, AIDS research and human retroviruses.

[37]  Tongqing Zhou,et al.  Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.

[38]  J. Mascola,et al.  Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. , 2007, Virology.

[39]  S. Harrison,et al.  Construction and characterization of a radio-iodinatable mutant of recombinant human CD4. , 1997, Journal of immunological methods.

[40]  J. Mascola,et al.  Anti-HIV-1 Response Elicited in Rabbits by Anti-Idiotype Monoclonal Antibodies Mimicking the CD4-Binding Site , 2008, PloS one.

[41]  D. Nickle,et al.  Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope , 2005, Journal of Virology.

[42]  T. Chun,et al.  Biochemical and Biological Characterization of a Dodecameric CD4-Ig Fusion Protein , 2002, The Journal of Biological Chemistry.

[43]  J. Mascola,et al.  Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys , 2005, Journal of Virology.

[44]  J. Balzarini,et al.  Human glutaredoxin-1 catalyzes the reduction of HIV-1 gp120 and CD4 disulfides and its inhibition reduces HIV-1 replication. , 2009, The international journal of biochemistry & cell biology.

[45]  S. Harrison,et al.  Peptide Ligands to Human Immunodeficiency Virus Type 1 gp120 Identified from Phage Display Libraries , 1999, Journal of Virology.

[46]  D. Montefiori,et al.  Induction of Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 Primary Isolates by Gag-Env Pseudovirion Immunization , 2005, Journal of Virology.

[47]  P. Earl,et al.  Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities , 1994, Journal of virology.

[48]  C. Broder,et al.  Inhibitors of Protein-Disulfide Isomerase Prevent Cleavage of Disulfide Bonds in Receptor-bound Glycoprotein 120 and Prevent HIV-1 Entry* , 2002, The Journal of Biological Chemistry.

[49]  Z. Xiang,et al.  Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding. , 2008, Virology.

[50]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.